New features of glatiramer acetate for the treatment of remitting multiple sclerosis

N. Y. Lasch

Open link

Publication date

December 2015

DOI

10.21518/2079-701X-2015-10-60-62

Publisher

Remedium, Ltd.

Journal

Meditsinskiy sovet = Medical Council

Abstract

The article discusses usage of the new dosage of glatiramer acetate (Copaxone®) for the treatment of relapsing-remitting multiple sclerosis. Results of phase II and III clinical trials are presented. Randomized clinical trials GALA and GLACIER demonstrated high efficacy, good safety and tolerability of glatiramer acetate taken in dosage 40mg/ml 3 times per week

Extracted data

We use cookies to provide a better user experience.

Data Protection

New features of glatiramer acetate for the treatment of remitting multiple sclerosis

Abstract

Extracted data

New features of glatiramer acetate for the treatment of remitting multiple sclerosis

Abstract

Extracted data

Related items

Related items